These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 11726197)

  • 1. Structure-function studies of linear and cyclized peptide antagonists of the GnRH receptor.
    Beckers T; Bernd M; Kutscher B; Kühne R; Hoffmann S; Reissmann T
    Biochem Biophys Res Commun; 2001 Dec; 289(3):653-63. PubMed ID: 11726197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of potent dicyclic (4-10/5-8) gonadotropin releasing hormone (GnRH) antagonists.
    Rivier JE; Struthers RS; Porter J; Lahrichi SL; Jiang G; Cervini LA; Ibea M; Kirby DA; Koerber SC; Rivier CL
    J Med Chem; 2000 Mar; 43(5):784-96. PubMed ID: 10715147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of potent dicyclic (1-5/4-10) gonadotropin releasing hormone (GnRH) antagonists.
    Rivier JE; Jiang G; Struthers RS; Koerber SC; Porter J; Cervini LA; Kirby DA; Craig AG; Rivier CL
    J Med Chem; 2000 Mar; 43(5):807-18. PubMed ID: 10715149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
    Schottelius M; Berger S; Poethko T; Schwaiger M; Wester HJ
    Bioconjug Chem; 2008 Jun; 19(6):1256-68. PubMed ID: 18510351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residues within transmembrane helices 2 and 5 of the human gonadotropin-releasing hormone receptor contribute to agonist and antagonist binding.
    Hoffmann SH; ter Laak T; Kühne R; Reiländer H; Beckers T
    Mol Endocrinol; 2000 Jul; 14(7):1099-115. PubMed ID: 10894158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel gonadotropin-releasing hormone antagonists with substitutions at position 5.
    Samant MP; Hong DJ; Croston G; Rivier C; Rivier J
    Biopolymers; 2005; 80(2-3):386-91. PubMed ID: 15614806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
    Fister S; Günthert AR; Aicher B; Paulini KW; Emons G; Gründker C
    Cancer Res; 2009 Aug; 69(16):6473-81. PubMed ID: 19638591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Phe313 of the gonadotropin-releasing hormone (GnRH) receptor as a site critical for the binding of nonpeptide GnRH antagonists.
    Cui J; Smith RG; Mount GR; Lo JL; Yu J; Walsh TF; Singh SB; DeVita RJ; Goulet MT; Schaeffer JM; Cheng K
    Mol Endocrinol; 2000 May; 14(5):671-81. PubMed ID: 10809231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of agonist but not antagonist leads to fluorescence resonance energy transfer between intrinsically fluorescent gonadotropin-releasing hormone receptors.
    Horvat RD; Roess DA; Nelson SE; Barisas BG; Clay CM
    Mol Endocrinol; 2001 May; 15(5):695-703. PubMed ID: 11328852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetrorelix, a gonadotropin-releasing hormone antagonist, induces the expression of melatonin receptor 1a in the gonadotropin-releasing hormone neuronal cell line GT1-7.
    Ishii H; Sato S; Yin C; Sakuma Y; Kato M
    Neuroendocrinology; 2009; 90(3):251-9. PubMed ID: 19641296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel cyclic azo-bridged analogs of gonadotropin-releasing hormone.
    Fridkin G; Rahimipour S; Ben-Aroya N; Kapitkovsky A; Di-Segni S; Rosenberg M; Kustanovich I; Koch Y; Gilon C; Fridkin M
    J Pept Sci; 2006 Feb; 12(2):106-15. PubMed ID: 16059965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of monocyclic (1-3) and dicyclic (1-3/4-10) gonadotropin releasing hormone (GnRH) antagonists.
    Rivier JE; Porter J; Cervini LA; Lahrichi SL; Kirby DA; Struthers RS; Koerber SC; Rivier CL
    J Med Chem; 2000 Mar; 43(5):797-806. PubMed ID: 10715148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
    Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M
    Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of novel bicyclic analogues derived from a potent oxytocin antagonist.
    Flouret G; Chaloin O; Borovickova L; Slaninová J
    J Pept Sci; 2006 Jun; 12(6):412-9. PubMed ID: 16432806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pituitary and gonadal effects of GnRH (gonadotropin releasing hormone) analogues in two peripubertal female rat models.
    Roth C; Hegemann F; Hildebrandt J; Balzer I; Witt A; Wuttke W; Jarry H
    Pediatr Res; 2004 Jan; 55(1):126-33. PubMed ID: 14605254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of gonadotropin-releasing hormone analogs based on a sensitive cellular luciferase reporter gene assay.
    Beckers T; Reiländer H; Hilgard P
    Anal Biochem; 1997 Aug; 251(1):17-23. PubMed ID: 9300077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats.
    Anderes KL; Luthin DR; Castillo R; Kraynov EA; Castro M; Nared-Hood K; Gregory ML; Pathak VP; Christie LC; Paderes G; Vazir H; Ye Q; Anderson MB; May JM
    J Pharmacol Exp Ther; 2003 May; 305(2):688-95. PubMed ID: 12606616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
    Manning M; Cheng LL; Stoev S; Wo NC; Chan WY; Szeto HH; Durroux T; Mouillac B; Barberis C
    J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma membrane expression of gonadotropin-releasing hormone receptors: regulation by peptide and nonpeptide antagonists.
    Finch AR; Caunt CJ; Armstrong SP; McArdle CA
    Mol Endocrinol; 2010 Feb; 24(2):423-35. PubMed ID: 20009083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix.
    Rozsa B; Nadji M; Schally AV; Dezso B; Flasko T; Toth G; Mile M; Block NL; Halmos G
    Prostate; 2011 Apr; 71(5):445-52. PubMed ID: 20859992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.